Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 781

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 781
---
 $ 1,964,000 and $ 2,035,000 as of December 31, 2023, and 2022, respectively. As of December 32, 2023, there was $ 796,000 of unrecognized stock compensation, which will be recognized over the next three years.

Note 11—Commitments and contingencies

Lease Commitments – The Company leases facilities under non-cancelable operating leases for the laboratory and offices in Tampa, Florida. The current lease was scheduled to expire in February 2024, but was amended in March 2024 to extend the expiry date to March 31, 2026.

Future minimum lease payments under these leases are as follows:

| Year ending December 31, 2024              
 Year ending December 31, 2025              |     |   | 21,002 
      — |   |
|:-------------------------------------------|:----|:--|-------:|:--|
|                                            |     |   | 21,002 |   |
| Interest portion of right of use liability |     |   |   (182 | ) |
| Right of use lease liability               |     | $ | 20,820 |   |

Total lease expense was approximately $ 192,000 and $ 193,000 for the years ended December 31, 2023, and 2022, respectively.

Employment Agreements– In July 2021, the Company signed a consulting agreement with the former CEO and President. In May 2023, the Company signed employment agreements with the CEO and CFO.

<div align='center'>F-6 0</div>

TUHURA BIOSCIENCES, INC. AND SUBSIDIARY Notes to the consolidated financial statements For the years ended December 31, 2023, and 2022

Future minimum payments under these employment and consulting agreements are as follows:

| Year ending December 31, 2024 
 Year ending December 31, 2025 |     |   |   683,000 
   499,000 |
|:------------------------------|:----|:--|----------:|
|                               |     | $ | 1,182,000 |

Note 12—Asset purchase On January 26, 2023 the Company acquired certain assets of TuHURA Biopharma, Inc for $ 1.2million in cash and 22.7million common shares. Dr. Bianco, President, Chief Executive Officer, and a